Literature DB >> 33891511

miR-21: A Key Small Molecule with Great Effects in Combination Cancer Therapy.

Nahid Arghiani1, Maryam M Matin1,2.   

Abstract

The increasing incidence of various cancers indicates the urgent need for finding accurate early diagnostic markers and more effective treatments for these malignancies. MicroRNAs (miRNAs) are small noncoding RNAs with great potentials to enter into cancer clinics as both diagnostic markers and therapeutic targets. miR-21 is elevated in many cancers, and promotes cell proliferation, metastasis, and drug resistance. In recent years, many studies have shown that targeting miR-21 combined with conventional chemotherapeutic agents could enhance their therapeutic efficacy, and overcome drug resistance and cancer recurrence both in vitro and in animal models. In this review, we first summarize the effects and importance of miR-21 in various cancers, and explore its function in drug resistance of cancer cells. Next, the challenges and prospects for clinical translation of anti-miR-21, as a therapeutic agent, will be discussed in combination cancer therapy.

Entities:  

Keywords:  cancer; combination therapy; drug resistance; miR-21

Mesh:

Substances:

Year:  2021        PMID: 33891511     DOI: 10.1089/nat.2020.0914

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  5 in total

Review 1.  Exosome-Mediated Response to Cancer Therapy: Modulation of Epigenetic Machinery.

Authors:  Mohammad Imran Khan; Reem K M E Alsayed; Hani Choudhry; Aamir Ahmad
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

Review 2.  Modulating microRNAs in cancer: Next-generation therapies.

Authors:  Nahid Arghiani; Khalid Shah
Journal:  Cancer Biol Med       Date:  2021-12-01       Impact factor: 4.248

Review 3.  MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes.

Authors:  Cyril Sobolewski; Laurent Dubuquoy; Noémie Legrand
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

Review 4.  Noncoding RNAs Emerging as Drugs or Drug Targets: Their Chemical Modification, Bio-Conjugation and Intracellular Regulation.

Authors:  Jin Wang; Tian Tian; Xin Li; Yan Zhang
Journal:  Molecules       Date:  2022-10-09       Impact factor: 4.927

5.  MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.

Authors:  Tong-Tong Li; Jie Mou; Yao-Jie Pan; Fu-Chun Huo; Wen-Qi Du; Jia Liang; Yang Wang; Lan-Sheng Zhang; Dong-Sheng Pei
Journal:  J Biomed Sci       Date:  2021-08-02       Impact factor: 8.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.